logo

Marker Therapeutics, Inc (MRKR)



Trade MRKR now with
  Date
  Headline
11/22/2022 7:27:48 AM Marker Therapeutics Announces FDA Clearance Of IND For MT-601 For Pancreatic Cancer
5/13/2022 7:42:49 AM Marker Therapeutics Q1 Net Loss $9.9 Mln Vs Loss Of $8.8 Mln Last Year
12/9/2021 7:07:36 AM Marker Therapeutics Appoints Biotech Executive Katharine Knobil To Board
7/6/2021 7:07:29 AM Marker Therapeutics Completes Safety Lead-In Portion Of Phase 2 Study In Post-Transplant AML
3/12/2021 8:02:12 AM Marker Therapeutics Prices Public Offering Of 28.57 Mln Shares At $1.75 Per Share
3/3/2021 7:06:48 AM Marker Therapeutics Doses First Patient In Phase 2 Trial Of MT-401 In AML Following Stem Cell Transplant
1/13/2021 7:19:37 AM Marker Completes Manufacturing Facility To Support Development Of MultiTAA-Specific T Cell Therapy Product Candidates
1/5/2021 7:04:54 AM Marker Therapeutics Says FDA Lifted Partial Clinical Hold On Phase 2 Trial Investigating Safety And Efficacy Of MT-401
3/29/2019 7:42:19 AM WBB Securities Ups Marker Therapeutics, Inc (MRKR) To Strong Buy From Buy With $12.50 Up From $5.50 Price Target